Vaccine against porcine salmonellosis
FIELD: veterinary science.
SUBSTANCE: vaccine against porcine salmonellosis contains cell suspension of attenuated vaccine strain Salmonella choleraesuis VGNKI SC 230-DEP in the following ratio of components, vol.-%: suspension of strain Salmonella choleraesuis VGNKI SC 230-DEP with concentration 100-120 billion cells in cm3, 42.0-55.0; sucrose, 5.0-7.5; gelatin, 1.5-2.0, and distilled water, the balance. Morbidity of piglets immunized with vaccine is reduced 2-fold and their safety is by 8.6% higher as compared with the same indices for piglets immunized with the known vaccine from the strain Salmonella choleraesuis VGNKI № 9. Vaccine shows enhanced economy in producing and exhibits stable genetic markers.
EFFECT: improved, enhanced and valuable properties of vaccine.
5 tbl, 8 ex
The invention relates to veterinary biotechnology, in particular to the means of specific prophylaxis of salmonellosis swine.
Salmonella choleraesuis is a common causative agent of salmonellosis animals of different species and primarily pigs, as well as one of the causative agents of foodborne diseases of man.
Damage to Salmonella choleraesuis, due to the high mortality of piglets, a common carrier in the adult population, the cost of the epidemic and therapeutic measures. The complexity of the fight against salmonellosis is determined by the rapid adaptation of the pathogen to antibiotics and other chemotherapeutic drugs. In this regard, in the first place in the fight against salmonellosis is vaccination using vaccines live attenuated strains.
Known vaccine against salmonellosis swine from the attenuated strain of Salmonella choleraesuis TS-177, which is a "wild" mutant, no genetic markers, in addition to reduced virulence .
Also known vaccine against salmonellosis swine of suppressor of revertant Salmonella choleraesuis VGNKI No. 9 . The strain of Salmonella choleraesuis VGNKI No. 9 differs from the epizootic strains of high frequency (up to 50%) selection streptomycetaceae mutants growing on nutrient content by stratum is the Qing 300 ág/cm 3, most of which remains virulent. Therefore, to differentiate vaccine strain from epizootic very difficult because of the need to examine a large number of mutant clones. In addition, the strain of Salmonella choleraesuis VGNKI No. 9 obtained as a result of mutations, which slowed its rate of reproduction is almost two times in comparison with the original strain. This significantly increases the costs of producing vaccines based on it.
The objective of the invention is the creation of a vaccine against salmonellosis swine on the basis of genetically labeled attenuated strain of Salmonella choleraesuis, high growth rate, the more pronounced immunogenicity, low residual virulence and stably preserving these properties.
The problem is solved by getting a vaccine containing a suspension of living microbial cells attenuated strain of Salmonella choleraesuis VGNKI SC 230-DEPT, sucrose, gelatin and distilled water in the following ratio of components,%:
Suspension of a strain of Salmonella choleraesuis SC 230-DEPT
with a concentration of 100-120 billion cells in 1 cm3- 42,0-55,0
Sucrose - 5,0-7,5
Gelatin - 1,5-2,0
Distilled water - the rest
Received the vaccine in contrast to known more effective as a tool for specific prevention of salmonellosis swine, more economical in production is, has a stable genetic markers.
Attenuated strain of Salmonella choleraesuis VGNKI SC 230-DEPT obtained by the method of insertional mutagenesis from a virulent strain of Salmonella choleraesuis VGNKI No. 95.
The strain of Salmonella choleraesuis SC 230-DEPT deposited in the collection of microorganisms of the all-Russian state research Institute for control, standardisation and certification of veterinary preparations and has a registration number SC 230-DEPT.
The strain of Salmonella choleraesuis SC 230-DEPT characterized by the following features.
The morphology. Bacterial cells are small gram-negative rods with a length of 1.0 to 1.5 μm and a width of 0.1 to 0.3 μm, motile with peritracheal located flagella, spores and capsules do not form.
Cultural characteristics. Cells of strains grow well on simple nutrient media. During growth on solid nutrient medium (MPA, environment Hottinger, nutrient agar “Difco”) at a temperature of 37°for 20-24 h grow colonies with a diameter of 1.0 to 1.5 mm in S-form: transparent, round, smooth, convex. With the growth in liquid nutrient medium is observed uniform clouding of the environment, characteristic for bacteria “smooth” type.
The nature of growth on nutrient media, the strain does not differ from epidemic strains of Salmonella choleraesuis.
Enzymatic properties. Sprayway with the formation of acid and gas CH is the goat, maltose, galactose, mannitol, sorbitol, xylose, rhamnose, dulcet, sodium citrate, glycerin, not sprayway sucrose, lactose, arabinose, Inositol, does not form indole, does not fold and not peptonized milk, forms a sulfide.
Antigenic structure is typical of Salmonella serovar Salmonella choleraesuis. Agglutinated Salmonella anoreceptive "O"sera: 6, 7, and "H"-sera specific phase - in and non phase - 1, 5.
Genetic markers. Strain resistant to rifampicin, streptomycin and trimethoprim. Markers of resistance remained stable periodic culturing the strain in a liquid medium (10 consecutive subcultures) and after three passages through white mice.
Virulence. the 50%lethal dose (LD50for white mice weighing 18-20 g is 10 million microbial cells (intraperitoneal infection).
Immunogenicity. A single subcutaneous immunization of mice weighing 16-18 g vibrant culture of the strain of Salmonella choleraesuis SC 230-DEPOT (103-106microbial cells) contributes to the prophylactics of infectious process after intraperitoneal infection (21 days after immunization) culture of a virulent strain of serovar Salmonella choleraesuis VGNKI No. 95 in a dose of 100 LD50. Survives from 80 to 100% of the immunized mice at 100%death unimmunized animals. ED501,4× 103microbial cells.
Morphological changes in the organs of immunized animals are characterized by diffuse and focal proliferation of lymphoid elements (increase regional and mesenteric lymph nodes) without necrobiotic processes in parenchymatous organs. Bacteria strain Salmonella choleraesuis SC 230-DEPT stored in mice within 15-22 days.
The basic properties of the strain of Salmonella choleraesuis SC 230-DEPT and vaccines obtained on its basis, are illustrated by the following examples.
Example 1. To obtain the attenuated strain of Salmonella choleraesuis use of a virulent strain of Salmonella choleraesuis VGNKI No. 95. Strain pre-labeled mutation rif, providing resistance to rifampicin. Selection Rifrmutants spend on a dense nutrient medium containing 100 µg/cm3rifampicin sowing 2×109microbial cell culture of a strain of Salmonella choleraesuis VGNKI No. 95.
To conduct insertional mutagenesis using transposon TP, included in the vector plasmati with temperaturescale replication DNA pVD3::Tn7 (TC Ar Km Sm Tp). Transfer of the plasmid into the recipient strain of Salmonella choleraesuis VGNKI No. 95-Rif is carried out in the conjugation crossing: E.coli JC 1553 (pVD3::Tn7) x Salmonella choleraesuis 95-Rifr. Select transconjugants Salmonella choleraesuis 95-Rif (pVD3::Tn7) phenotype Rifr(determined rif-mu is a situation of strain) Tc rAprKmr(markers plasmids pVD3) TprSmr(marker transposon Tn7) .
For selection of insertional mutants of Salmonella choleraesuis 95-Rif (pVD3::Tn7), grown at a temperature of 31°in L-broth and plated on solid medium containing streptomycin (40 mg/ml) or trimethoprim (50 µg/ml), and incubated at a temperature of 43°C. The grown clones checks deselectitem markers vector plasmids (Cu Km Ar) and select options, containing only markers Tn7 (Sm Tp), i.e. clones with Tn7 insertion. Assess the virulence of insertional mutants in experiments by intraperitoneal infection of white mice and select strains with reduced virulence. The strain of Salmonella choleraesuis SC 230-DEPT analyzed 60 insertional mutants of a virulent strain of Salmonella choleraesuis VGNKI No. 95.
Example 2. The study of the stability of genetic markers attenuated strain of Salmonella choleraesuis SC 230-DEPT.
Explore the preservation of markers of resistance to streptomycin (Sm) and trimethoprim (Tp) transposon Tn7, the insertion of which led to attenuate strain SC 230, periodic cultivation of this strain in L-broth (LB) and in the same conditions with subsequent infection of white mice and analysis extracted from infected culture. In both cases, the culture of the strain after the completion of the experiment clone on PLO is Noah nutrient medium and detect the presence of markers Sm rand Trrnot less than 50 clones. The results of the experiments are presented in table 1.
Example 3. Determination of the residual virulence of the attenuated strain.
White mice weighing 18-20 g infect intraperitoneally agar suspension culture Salmonella choleraesuis SC 230-DEPT; infecting dose of 105, 106, 107, 108microbial cells. Control group animals infect the culture of a virulent strain of Salmonella choleraesuis VGNKI No. 95. Animals observed 21 days. In these experimental conditions LD50Salmonella choleraesuis SC 230-DEPT calculated from Cerberus, ranges from 5×106up to 5×107cells, LD50the strain of Salmonella choleraesuis VGNKI No. 95 - 10-100 cells. Thus, the residual virulence of the strain of Salmonella choleraesuis SC 230-DEPT for white mice in 100000 times lower compared to the virulence of the original strain.
Example 4. The protective properties of the attenuated strain of Salmonella choleraesuis SC 230-DEPT determined in experiments on white mice. White mice weighing 16-18 g subcutaneously injected a suspension of attenuated strains at a dose of 1×104microbial cells. After 20 days of immunized and unimmunized animals infect 100 LD50virulent strain of Salmonella choleraesuis VGNKI No. 95.
Comparative results of the three experiments to determine the protective properties of the attenuated strain of Salmonella choleraesuis SC 230-DEPT is redstavleny in table 2.
Example 5. The ability of the attenuated strain of Salmonella choleraesuis SC 230-DEPT prevent salmonellosis swine determine on pigs. Pigs 20-25 days of age intramuscularly injected a suspension of attenuated strains at a dose of 5×108microbial cells. After 21 days of immunized and unimmunized animals intraperitoneally infect the culture of a virulent strain of Salmonella choleraesuis VGNKI No. 95 at a dose of 4×1010microbial cells. The results of two experiments are presented in table 3. Immunization of piglets attenuated strain of Salmonella choleraesuis SC 230-DEPT protects from death after infection with a virulent strain of 90% of the animals at 100%mortality in the control group.
Example 6. The production of vaccines against salmonellosis from a strain of Salmonella choleraesuis SC 230-DEPT.
In the reactor broth of Hottinger (300 l) make macrovu seed is obtained microbial cells of strain based 35 million/cm3. Centrifuged at 15K rpm for 60 minutes. The bacterial mass is mixed with the gelatin saharovym stabilizer in a ratio of 1:2.
The vaccine is filled into ampoules of 4 cm3and lyophilizers.
The vaccine series 1 has the following composition,% :
Suspension of a strain of Salmonella choleraesuis SC 230-DEPT
with a concentration of 100-120 billion cells in 1 cm3- 55,0
Sucrose - 7,5
Gelatin - 2,0
Distilled water - the restThe vaccine series 2 has the following composition,%:
Suspension of a strain of Salmonella choleraesuis SC 230-DEPT
with a concentration of 100-120 billion cells in 1 cm3- 42,0
Sucrose - 5,0
Gelatin - 1,5
Distilled water - the rest
Example 7. The harmlessness of the proposed vaccine largest tolerated dose was studied on white mice, Guinea pigs and piglets. These experiments are summarized in table 4.
From the data presented in table 4, it is seen that a portable dose of vaccine does not cause the death of the mice, 5×105and 1.0×105once below the minimum lethal dose of a virulent strain of Salmonella choleraesuis VGNKI No. 95 respectively in subcutaneous and oral infection.
Example 8. A method for preventing salmonellosis swine includes a twofold administration of the vaccine to piglets at the age of 10-12 and 18-20 days at a dose of 500 million microbial cells.
Tested vaccine from strain Salmonella choleraesuis SC 230-DEPT and Salmonella choleraesuis VGNKI No. 9 for the prevention of salmonellosis swine.
From the data presented in table 5, it follows that the incidence of pigs immunized with the proposed vaccine from strain Salmonella choleraesuis SC 230-DEPT, 2 times lower, and the safety of 8.6% higher compared with the same indicators for a group of pigs immunized with the vaccine of the strain of Salmonella choleraesuis VGNKI No. 9.
Sources of information
1. Veterinary legislation is. T.1.- M.: Kolos, 1973.- S.
2. As the USSR №1577116, 1988
3. Volgenau NV, torch E.A., barzilov A.I. and other Receiving vaccine strains of Salmonella using insertional mutagenesis //veterinary - 1997, No. 9, p.20-24.
The stability of inheritance of genetic markers in attenuated strain of Salmonella choleraesuis SC 230-DEPT
|Conditions of cultivation||% of clones containing the token||Agglutination serum O7|
|10 sequential subcultures in LB||100||100||+|
|10 transfers in LB+3-fold passage through the white mice||100||100||+|
The protective properties of the strain of Salmonella choleraesuis SC 230-DEPT experiments on mice
|A group of mice||Experience No.||The number of mice in the experience||Results infection|
The protective properties of the strain of Salmonella choleraesuis SC 230-DEPT experiments on pigs
|A group of pigs||Experience No.||The number of piglets in the experience||Results infection|
The safety of the vaccine for laboratory animals and piglets
|Animals||The method of vaccine administration||Portable dose (MIC. CL vaccine strain)||The minimum lethal dose of a virulent strain (MIC. CL)|
|White mice (weighing 16-18 g)||Subcutaneous||1,0×107||20|
|Guinea pigs (weighing 300-350g) Piglets (12-15 days)||Subcutaneous||2,0×1010||1,0×109|
The effectiveness of live vaccines against salmonellosis swine in the application of the proposed method for the prevention of salmonellosis swine
|Type of vaccine||Taken in the experience goals||Sore heads (%)||Palo heads (%)||With the preservation, %|
|Vaccine against salmonellosis swine from a strain of Salmonella choleraesuis SC 230-DEPT||670||31(4,6)||19(2,8)||92,5|
|Dried live vaccine from strain Salmonella choleraesuis No. 9||810||77(9,5)||53(6,5)||83,9|
Vaccine against salmonellosis swine containing cell suspension vaccine strain, sucrose, gelatin and distilled water, characterized in that as the vaccine strain it contains attenuated strains of Salmonella choleraesuis VGNKI SC 230-DEPT in the following ratio of components,%:
Suspension of a strain of Salmonella choleraesuis VGNKI SC 230-DEPT concentration of 100-120 merdek 1 cm342,0-55,0
Distilled water the Rest
FIELD: biotechnology, in particular immunological and genetic investigations and educatory process.
SUBSTANCE: Claimed avirulent strain of bacteria Vibrio cholerae biovar eltor, serovar Ogava (ctxA-, tcpA-, toxR-, zot-) is isolated from natural water source of open basin in Turkmenistan, doesn't contain ctxA, tcpA, toxR, zot genes and has stable avirulent atoxigenic properties for long-time storage.
EFFECT: strain useful in screening of new drugs for cholera immunoprophylaxis, including ones being obtained by gene engineering methods; as well as in various educatory processes.
FIELD: biotechnology, medicine, veterinary, in particular drug for treatment and prevention of cow endometritis.
SUBSTANCE: claimed biological preparation contains dry biomass of strain Bifidobacterium pseudolongum N 533 and strain Lactobacillus salivarius N 117. Strains are cultivated separately on broth providing accumulation of necessary biomass. Biomass is concentrated by centrifugation and mixed with safety medium in ratio of 1:1-1:2, respectively. Obtained suspensions of B. pseudolongum N 533 and L. salivarius N 117 biomasses are blended in equal amounts, bottled into 2-4 ml bijous and dried.
EFFECT: preparation with high adhesion, antagonistic activity to opportunistic and pathogenic microflora and increased therapeutical effectiveness.
1 tbl, 2 ex
FIELD: biotechnology, microbiology, broth for bifidus bacteria cultivation.
SUBSTANCE: claimed broth for bifidus bacteria cultivation contains as main component pancreatic protein hydrolyzates of casein or forcemeat containing 700-900 mg% of amine nitrogen. Hydrolyzable mixture additionally contains 20-40 g/l of cow or pork liver waste. Broth also contains sodium chloride 4.0-5.0 g; L-cystine hydrochloride 0.10-0.15; microbiological agar 0.75-1.00 g; yeast autolyzate 300.0-400.0 ml; pancreatic casein hydrolyzate containing 700-900 mg% of amine nitrogen, diluted with distilled water up to amine nitrogen content of 140-160 mg%, 300.0-350.0 ml; pancreatic forcemeat hydrolyzate containing 700-900 mg% of amine nitrogen, diluted with distilled water up to amine nitrogen content of 140-160 mg%, 300.0-350.0 ml; 40 % lactose solution 25.0 ml.
EFFECT: new nutrient medium completely satisfying to bacterium population requirements.
2 cl, 3 tbl, 3 ex
FIELD: biotechnology and medical biology.
SUBSTANCE: invention relates to treatment preparation based on lactic bacteria of strain Lactobacillus acidophilus. Preparation contains 1.0-99.0 mass % of biomass of living bacteria Lactobacillus acidophilus N.V. Ep 317/402-X and balance: biomass of bacteria Lactobacillus acidophilus N.V. Ep 317/402-X, exposed to multiple freezing and thawing or autolysis, as source of cell detritus, extracellular and intracellular metabolites. Additionally preparation comprises 0.5-30.0 mg/ml of lysozyme and/or 0.001-0.1 mg/ml of nisin.
EFFECT: preparation with wide range of antagonistic activity, particularly in relation to pathogenic bacteria Helicobacter pylori associated with various forms of gastritis and duodenal and stomach ulcer, and high content of valuable substances.
2 cl, 2 tbl, 9 ex
FIELD: biotechnology, in particular deep cultivation of Bacillus circulans.
SUBSTANCE: invention relates to deep cultivation of pectin-lyase producer such as Bacillus circulans, liquid standardization thereof and drying of cultural liquid or filtrate thereof. Cultural broth contains maize flour (2.75-3.0 %) or maize starch (2.75 %) or mixture of maize flour (3 % or less) with wheal bran (4 % or less). Method includes pH changing of filtrate or cultural liquid standardized with salts before dehydration. Changing of broth composition males it possible to obtain increased productivity of pectin-lyase biosynthesis process (up to 34100 U/cm3, to increase enzyme heat resistance up to 85.1 % (based on starting level); and changing of pH value (from 6.0 to 7.8) makes it possible to additionally increase of heat resistance up to 12.2 %.
EFFECT: bacterial enzyme with increased heat resistance.
2 tbl, 4 ex
FIELD: biotechnology and agriculture, in particular probiotic-containing compound feed for domestic animals, birds and fish.
SUBSTANCE: claimed additive is prepared by mixing of subtilis B-2250 and/or Bacillus licheniformis B-2252 biomass and carrier-sorbent and moisture capacitive filler as auxiliary substances. As carrier-sorbent hydrophilic and hydrophobic substances are used, and as moisture capacitive filler cation exchanging resins are used in predetermined ratio of dry mass. Probiotic additive in dry microcapsulated form is obtained by capillary sorptive drying of component mixture up to finished product humidity of 8-25 %.
EFFECT: probiotic additive with stable properties capable to improve feed conversion, to increase weight increment and to reduce animal mortality.
2 cl, 2 tbl, 4 ex
FIELD: medicine, in particular clinical microbiology.
SUBSTANCE: Claimed broth contains potassium dihydrophosphate, anhydrous disodium phosphate, magnesium sulfate, iron ammoniumcitrate, sodium citrate, glycerol, sodium hydro-L-glutaminate, thiamine bromide, manganese (II) sulfate, distillated water, normal horse serum and at least one antituberculosis preparation: rifampicin, streptomycin, isoniazide, ethambutol. Method of present invention is useful in accelerated determination of tuberculosis mycobacterium drug resistance.
EFFECT: broth with increased growth properties, simplified visual profitability analysis.
2 tbl, 3 ex
FIELD: microbiology, medicine.
SUBSTANCE: invention relates to method of diagnosis and treatment of intestinal yersinioses and pseudotuberculosis. Claimed method includes Yersinia enterocolitica and Yersinia pseudotuberculosis isolation from clinic and other material. Broth (I-agar) contains (g/l): peptone 19.0-21.0; yeast extract 1.9-2.1; mannitol 19.0-21.0; sodium pyruvate 1.9-2.1; sodium chloride 0.95-1.05; magnesium sulfate 0.009-0.011; sodium deoxycholeta 0.48-0.53; neutral red 0.028-0.032; crystal violet 0.009-0.0011; agar-agar 11.9-13.1; irgasane 0.0039-0.0041; and balance: distilled water.
EFFECT: simplified broth composition with improved selectivity to Y. pseudotuberculosis without essential alteration of other medium characteristics.
3 tbl, 1 ex
FIELD: biotechnology, microbiology, in particular broth production for cultivation of bifidobacteria and lactobacillus.
SUBSTANCE: claimed method includes water-based broth production. Water used for broth production is pretreated by non-filtered modulated ultraviolet light containing in radiant flux not less than 30 % of ultraviolet quantum with wave length less than 350 nm, for period sufficient to increase water intrinsic energy by not less than 2 times. Method also includes measurement of water intrinsic energy variation before treatment and during whole treatment process.
EFFECT: microorganisms with activated cultural properties; decreased cultivation time.
5 tbl, 2 ex
FIELD: foodstuff industry, biotechnology, agriculture.
SUBSTANCE: Propionibacterium acnes strain Ac-1450/26 is produced by multiple reseeding cells of starting Propionibacterium acnes Ac-1450 strain, deposited in All-Russian State collection of microorganism strains for veterinary and stockraising. Said strain represents a producer of foodstuff protein. Using of foodstuff protein producing strain makes it possible to avoid environment pollution when manufacturing of protein foodstuff, to increase protein specific yield, to simplify and accelerate manufacturing process, to simplify equipment and utilize waste of industries using natural raw materials.
EFFECT: improved and environmentally friendly method for producing of protein foodstuff.
2 tbl, 10 ex
SUBSTANCE: the present innovation deals with the ways for body purification and detoxication with the help of products of plant origin. The method includes preliminary period at additional survey for the presence of parasites followed by body purification due to curative starvation: during the first day a patient should apply nocturnal purifying enema, next morning - saline purgative preparation, then during the second and next day of starvation it is prescribed the intake of not less than 1-1.5 l water at daily application of purifying enemas for the whole period of starvation, and restorative period at applying juice-fruit-vegetable diet. Moreover, at the background of starvation, one should perform hepatic purification and that of gastro-intestinal tract along with body disinfection and withdrawal of parasites: at 7 p.m. during the 1st d of starvation a patient should apply 150 mg decaris, daily since the 1st d to the 7th d of starvation it is necessary to use decoctions of cholagogue, diuretic and antiparasitic herbal species. Since the 4th d of starvation one should add the intake of garlic decoction based upon milk, on the 3d, 5th, 7th d of starvation it is necessary to fulfill hepatic tubing at 7 p.m. after the intake of natural apple juice at 4 p.m., moreover, on the 3d d of starvation tubing should be conducted after the intake of vegetable oil in lemon juice, 4 times, on the 5th d - after the intake of cholagogue species, 4 times, on the 7th d - after the intake of purgative species with sorbitol. During the 1st d of starvation end one should perform parasitic disinfection due to the intake of acid milk whey to one's empty stomach, in 30-40 min -herring without bread, in 2 h - a glass of warm, sweet milk and application of purifying enema in 6-8 h. The method provides simultaneous restoration of affected body metabolism, hepatic purification and that of gastro-intestinal tract followed by withdrawal of parasites.
EFFECT: higher efficiency of body healing.
6cl, 2 ex, 1 tbl
FIELD: medicine, microbiology.
SUBSTANCE: method involves applying hydrogen sulfide mineral water from the health resort "Ust-Kachka" with the total mineralization 76 g/dm3. Invention promotes to enhancing sensitivity of microorganisms to antibacterial preparations that, in turn, promotes to reducing doe of the latter and prophylaxis of iatrogenic complications associated with carrying out antibacterial therapy. Invention can be used for enhancing sensitivity of microorganisms to antibacterial preparations.
EFFECT: valuable properties of agent.
3 tbl, 3 ex
FIELD: medicine, biochemistry.
SUBSTANCE: invention proposes applying CDP-choline (cytidinediphosphocholine) or its salt as a prophylactic agent for treatment of cerebral ischemia and a method for such prophylactic treatment. Invention found new and unknown early mechanism of action of CDP-choline or its salt: inhibition of activation of caspase cascade being the effectiveness of this effect is high in prophylactic intake of drug.
EFFECT: valuable medicinal properties of agent.
6 cl, 5 dwg, 4 ex
FIELD: medicine, surgery.
SUBSTANCE: method involves administration of verapamil solution in the amount 20-30 mg by intraperitoneal route by spraying method on visceral and parietal peritoneum on the final stage of operation. Invention promotes to reducing frequency in formation and relapse of post-operative adhesions. Invention can be used for prophylaxis of post-operative adhesions.
EFFECT: improved method for prophylaxis.
FIELD: medicine, obstetrics.
SUBSTANCE: at the first stage of pregravidic training one should introduce leukinferon per 10000 IU intramuscularly every other day 10 times, at the second stage it is necessary to perform 3 seances of discrete plasmapheresis. The present innovation enables to decrease the frequency in developing gestosis and the risk for abortion due to normalized activity of female immune system, that in its turn, enables to stop virusemia and virusuria, prevent fetoplacental failure and intrauterine fetal infectioning.
EFFECT: higher efficiency of training.
3 ex, 1 tbl
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new derivatives of glucopyranosyloxybenzylbenzene represented by the formula (I): wherein R1 represents hydrogen atom or hydroxy(lower)alkyl; R2 represents lower alkyl group, lower alkoxy-group and lower alkylthio-group being each group is substituted optionally with hydroxy- or (lower)alkoxy-group, or to its pharmaceutically acceptable salts. Also, invention relates to pharmaceutical composition eliciting hypoglycemic activity and to a method for treatment and prophylaxis of hyperglycemia-associated diseases, such as diabetes mellitus, obesity and others, and to their intermediate compounds. Invention provides preparing new derivatives of glucopyranosyloxybenzylbenzene that elicit the excellent inhibitory activity with respect to human SGLT2.
EFFECT: valuable medicinal properties of compounds.
13 cl, 2 tbl, 2 ex
FIELD: chemical and pharmaceutical industry, in particular method for production of healthful and therapeutic composition based on plant raw materials.
SUBSTANCE: claimed method includes separate preparation of fine dispersed powder of at least one plant with crushing degree of 10-200 mum; separate extraction of at least one plant with aqueous ethanol in ratio raw material/extractant from 1:5 to 1:20, respectively; separate preparation and optionally concentration of at least one plant juice followed by blending of obtained powder, extract and juice in ratio of (1-20):(9-90):(9-90), respectively.
EFFECT: new healthful and therapeutic composition with increased content of vitamins, proteins, carbohydrates, flavonoids, etc. and improved action on organism.
4 cl,4 ex, 1 tbl
FIELD: veterinary science.
SUBSTANCE: one should apply a honey-tissue preparation that contain emulsion out of the walls of pregnant uterus and ovaries without cow's yellow bodies 6.0 ml, natural bee honey 5.0 g, isotonic sodium chloride solution 2.0 ml sodium benzoate caffeine 1.5 g to be introduced into dorsal lumbar muscles both from the right and from the left per a half of the dosage being equal to 0.03-0.04 ml/kg either once or twice at 6-7-d-long interval. The present innovation enables to improve metabolism, normalize the work of hormonal and nervous systems, normalize functions of uterine muscles at hypo- and atonias, at delayed afterbirth and restore affected ovarian functions.
EFFECT: higher efficiency of therapy.
FIELD: medicine, anesthesiology, traumatology, orthopedics, thoracic surgery.
SUBSTANCE: about 1.5-2 min before spreading the affected lung it is necessary to deepen anesthesia due to injecting phenthanyl at the dosage of 10-12 mcg/kg body weight. The present innovation provides safety of operations of ventral spondyledesis out of transthoracic and thoracodiaphragmatic accesses, stability of arterial pressure level and patient's heart rate, decreases stress loading upon a patient that, in its turn, favors the prophylaxis of intraoperative complications.
EFFECT: higher efficiency of anesthesiological protection.
2 cl, 1 ex
FIELD: medicine, obstetrics, gynecology, mammology.
SUBSTANCE: method involves administration of alcohol-air mixture into cyst cavity wherein the amount of air and alcohol is similar and represents 40-60% of the content volume evacuated from the cyst cavity. Invention promotes to prophylaxis of diseases relapses and prevention of iatrogenic complications associated with carrying out this procedure. Invention can be used for treatment of patients with cystic mactopathy.
EFFECT: improved method for treatment.
FIELD: biotechnology, genetic engineering, molecular biology.
SUBSTANCE: invention proposes recombinant DNA pcDNA-TCI that has molecular mass 4.3 x 103 kDa and size 6 657 nucleotide pairs. The proposed recombinant plasmid DNA provides expression of artificial gene TCI comprising cytotoxic T-cellular epitopes of HIV-1 in eucaryotic cells. Also, invention proposes recombinant attenuated strain of bacterium Salmonella enteritidis E-23 pcDNA-TCI. The proposed strain is obtained by genetic transformation of the strain Salmonella enteritidis E-23 with plasmid pcDNA-TCI. The strain provides delivery DNA-vaccine in eucaryotic cells as the recombinant plasmid DNA pcDNA-TCI. Proposed groups of inventions provide inducing the expressed specific humoral and cellular immune response to HIV-1 in body. Proposed group of inventions can be used in medicine and virology for construction of live DNA-vaccine against HIV-1.
EFFECT: valuable biological and medicinal properties of strain and vaccine.
2 cl, 3 dwg, 3 tbl, 5 ex